These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 3768256

  • 21. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH, Brøsen K, Hansen MG, Aaes-Jørgensen T, Overø KF, Gram LF.
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [Abstract] [Full Text] [Related]

  • 22. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
    Gram LF, Brøsen K.
    Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
    [Abstract] [Full Text] [Related]

  • 23. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
    Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ.
    Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
    [Abstract] [Full Text] [Related]

  • 24. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.
    Horai Y, Ishizaki T, Eichelbaum M, Hashimoto K, Chiba K, Dengler HJ.
    Xenobiotica; 1988 Sep; 18(9):1077-84. PubMed ID: 3227705
    [Abstract] [Full Text] [Related]

  • 25. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K, Otton SV, Gram LF.
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [Abstract] [Full Text] [Related]

  • 26. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
    Nielsen F, Rosholm JU, Brøsen K.
    Eur J Clin Pharmacol; 1995 Nov; 48(6):501-4. PubMed ID: 8582470
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
    Sindrup SH, Brøsen K, Gram LF.
    Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K, Gram LF.
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [Abstract] [Full Text] [Related]

  • 32. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
    Milejski P, Orzechowska-Juzwenko K, Niewiński P, Hurkacz M, Czarnik-Matusewicz H, Forkasiewicz Z, Dawiskiba J, Bednarz W, Domosławski P.
    Endokrynol Pol; 2006 Apr; 57(6):605-11. PubMed ID: 17253433
    [Abstract] [Full Text] [Related]

  • 33. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
    Paar WD, Poche S, Gerloff J, Dengler HJ.
    Eur J Clin Pharmacol; 1997 Apr; 53(3-4):235-9. PubMed ID: 9476037
    [Abstract] [Full Text] [Related]

  • 34. Polymorphic drug oxidation in humans.
    Eichelbaum M.
    Fed Proc; 1984 May 15; 43(8):2298-302. PubMed ID: 6714436
    [Abstract] [Full Text] [Related]

  • 35. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH, van der Wart JH, Brugman M, Breimer DD.
    J Pharmacol Exp Ther; 1989 May 15; 249(2):638-45. PubMed ID: 2724144
    [Abstract] [Full Text] [Related]

  • 36. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F, Vandamme N, Libersa C, Lhermitte M.
    Br J Clin Pharmacol; 1991 Oct 15; 32(4):459-66. PubMed ID: 1958440
    [Abstract] [Full Text] [Related]

  • 37. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H, Hansen TS, Brøsen K.
    Pharmacogenetics; 1996 Dec 15; 6(6):513-9. PubMed ID: 9014200
    [Abstract] [Full Text] [Related]

  • 38. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
    Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ.
    Eur J Clin Pharmacol; 1979 Sep 15; 16(3):183-7. PubMed ID: 499318
    [Abstract] [Full Text] [Related]

  • 39. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T, Jurima M, Nakano M, Kalow W.
    Clin Pharmacol Ther; 1984 Nov 15; 36(5):670-6. PubMed ID: 6488688
    [Abstract] [Full Text] [Related]

  • 40. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi MN, Eichelbaum M, Jaillon P, Funck-Brentano C.
    Clin Pharmacol Ther; 1996 May 15; 59(5):583-92. PubMed ID: 8646830
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.